TD Cowen raised the firm’s price target on McKesson (MCK) to $820 from $695 and keeps a Buy rating on the shares. The firm updated its estimates following Q4 results which assume no sale of the Med-Surg segment and includes contributions from FCS and PRISM Vision.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strong Financial Outlook and Strategic Initiatives Lead to Buy Rating and Increased Price Target
- McKesson’s Earnings Call: Record Growth Amid Challenges
- McKesson price target raised to $800 from $755 at BofA
- McKesson’s Strategic Focus and Strong Financial Performance Justify Buy Rating
- McKesson’s Strategic Focus and Growth Potential: Buy Rating Affirmed